Published in Nature on May 27, 2004
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest (2009) 1.72
Targeting the human cancer pathway protein interaction network by structural genomics. Mol Cell Proteomics (2008) 1.54
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene (2007) 1.49
An integrative analysis of microRNA and mRNA expression--a case study. Cancer Inform (2008) 1.30
Evolutionary concepts in biobanking - the BC BioLibrary. J Transl Med (2009) 1.29
Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med (2011) 1.27
Cancer driver mutations in protein kinase genes. Cancer Lett (2008) 1.24
Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol (2009) 1.15
Prostate cancer regulatory networks. J Cell Biochem (2009) 0.91
Incorporating the human gene annotations in different databases significantly improved transcriptomic and genetic analyses. RNA (2013) 0.82
Cancer metabolism: strategic diversion from targeting cancer drivers to targeting cancer suppliers. Biomol Ther (Seoul) (2015) 0.80
An Empirical Evaluation of Normalization Methods for MicroRNA Arrays in a Liposarcoma Study. Cancer Inform (2013) 0.79
Human cancer classification: a systems biology- based model integrating morphology, cancer stem cells, proteomics, and genomics. J Cancer (2011) 0.78
Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases. J Transl Med (2015) 0.78
Discovery of a new biomarker for gastroenterological cancers. J Gastroenterol (2005) 0.78
Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids. Eur J Med Chem (2015) 0.77
Differences in the binding affinities of ErbB family: heterogeneity in the prediction of resistance mutants. PLoS One (2013) 0.76
Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis. J Transl Med (2017) 0.75
Shock the heat shock network. J Clin Invest (2009) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A (2002) 4.45
Long-range heterogeneity at the 3' ends of human mRNAs. Genome Res (2002) 3.91
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
High-throughput SELEX SAGE method for quantitative modeling of transcription-factor binding sites. Nat Biotechnol (2002) 3.04
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci U S A (2003) 2.64
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 2.61
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci U S A (2009) 2.57
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res (2003) 2.53
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
An atlas of human gene expression from massively parallel signature sequencing (MPSS). Genome Res (2005) 2.39
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A (2005) 2.38
A mouse atlas of gene expression: large-scale digital gene-expression profiles from precisely defined developing C57BL/6J mouse tissues and cells. Proc Natl Acad Sci U S A (2005) 2.35
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
Swine and poultry pathogens: the complete genome sequences of two strains of Mycoplasma hyopneumoniae and a strain of Mycoplasma synoviae. J Bacteriol (2005) 2.15
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res (2008) 2.14
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res (2007) 2.08
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
Sequence-based cancer genomics: progress, lessons and opportunities. Nat Rev Genet (2003) 2.01
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 1.94
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood (2005) 1.84
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 1.82
Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res (2002) 1.81
Nineteen additional unpredicted transcripts from human chromosome 21. Genomics (2002) 1.80
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A (2007) 1.79
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A (2006) 1.77
Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res (2005) 1.75
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res (2005) 1.75
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67
The genome sequence of the gram-positive sugarcane pathogen Leifsonia xyli subsp. xyli. Mol Plant Microbe Interact (2004) 1.65
Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg (2012) 1.60
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A (2003) 1.56
Autoantibodies against cancer antigens. Methods Mol Biol (2009) 1.54
A survey of glioblastoma genomic amplifications and deletions. J Neurooncol (2009) 1.52
Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol (2012) 1.51
CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A (2009) 1.51
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A (2012) 1.51
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res (2012) 1.49
A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest (2004) 1.48
Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A (2010) 1.46
The SSX gene family: characterization of 9 complete genes. Int J Cancer (2002) 1.46
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res (2002) 1.46
Bioinformatics construction of the human cell surfaceome. Proc Natl Acad Sci U S A (2009) 1.45
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res (2004) 1.44
Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods (2008) 1.43
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res (2004) 1.41
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood (2006) 1.41
In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest (2006) 1.41
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res (2006) 1.41
Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci U S A (2005) 1.39